Despite the recent progress in checkpoint inhibitor therapy, there remains an unmet need to further improve the outcomes of patients with advanced melanoma. Here, we report one-year data from a phase 2 study, assessing safety, efficacy and immunogenicity of the personalized neoantigen (neoAg) peptide vaccine, EVX-01, combined with pembrolizumab in advanced melanoma (NCT05309421). In this study, we identified and selected tumor-specific neoAgs based on tumor DNA- and RNA-sequencing data using the proprietary vaccine target discovery platform, AI-ImmunologyTM.
The top-ranked neoAgs for each patient were manufactured as synthetic long peptides (max. 10 neoAgs) and formulated with a liposomal adjuvant, creating the personalized cancer vaccine, EVX-01, tailored to each patient’s individual tumor and immune system characteristics.
